- Record: found
- Abstract: found
- Article: not found
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang
1 ,
Eric Van Cutsem ,
Andrea Feyereislova ,
Hyun C Chung ,
Lin Shen ,
Akira Sawaki ,
Florian Lordick ,
Atsushi Ohtsu ,
Yasushi Omuro ,
Taroh Satoh ,
Giuseppe Aprile ,
Evgeny Kulikov ,
Julie Hill ,
Michaela Lehle ,
Josef Rüschoff ,
Yoon-Koo Kang
Aug 28 2010
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer.